TELA Bio
TELA
45 hedge funds and large institutions have $19.3M invested in TELA Bio in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
25% more funds holding
Funds holding: 36 → 45 (+9)
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
16% more capital invested
Capital invested by funds: $16.7M → $19.3M (+$2.62M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.55% less ownership
Funds ownership: 60.07% → 57.51% (-2.6%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$614K |
| 2 |
WA
WealthTrust Axiom
Wayne,
Pennsylvania
|
+$66.1K |
| 3 |
Jane Street
New York
|
+$40.3K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$37K |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$22.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$839K |
| 2 |
Citigroup
New York
|
-$612K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$99.9K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$81.5K |
| 5 |
BlackRock
New York
|
-$74.7K |
TELA Hedge Fund Activity: Q2 2026 in Review
45 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in TELA Bio (TELA) for Q2 2026, worth a combined $19.3M — up 16% from $16.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TELA positions and 1 closed out — a net gain of 9 holders — while 12 added to existing stakes and 10 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $614K. The largest seller was UBS Group, cutting an estimated $839K.
- 45 institutional investors held TELA Bio (TELA) as of Q2 2026, up from 36 in Q1 2026.
- Funds reported $19.3M of TELA Bio stock for Q2 2026, up 16% quarter-over-quarter.
- 10 funds opened new TELA Bio positions in Q2 2026 and 1 closed out, a net change of +9 holders.
- The largest TELA Bio buyer in Q2 2026 was Nantahala Capital Management, an estimated $614K added.
- The largest TELA Bio seller in Q2 2026 was UBS Group, an estimated $839K sold.
Based on aggregated 13F filings for Q2 2026.